NICE ME/CFS Guideline stakeholder scoping workshop, Fri 25th May 2018

The only reason I was uncertain was that it hadn’t appreciated your first point – that physicians can prescribe these things anyway. Given that, I think you’re absolutely right.
Good luck finding a physician that will prescribe B12 injections. If it' s not a defined treatment noone will stick their neck above the parapet and prescribe it. Incredibly hard to get, though other fatiguing illnesses have no problems.
Please also do not think it is harmless. Sublingual B12 caused temporary blindness in my aunt ( noone seens to quite know why)
 
Page two of the slide presentations issued to us on Friday;

What does the scope do?
  • Ensures the guideline addresses the key areas of variation in delivery of care and quality

How on earth can this be achieved? There appears no formal mechanism for feedback to NICE about "variation", care or quality!!.
NHS England and NHS Public Health have not addressed this.

Government (D o H and SC) don't collect data on ME CFS Services-
Not all services subscribe to "BACME"-
One of the informed stakeholders involve in NICE before and with BACME (medic) gave out some statistics which are not common knowledge (only 9% of services have a lead ( consultant level?) physician) , most are therapy OT and Physio led; annual average "spend" on a MS patient £80, and ME patient averaged at £4 I think she said (will have to check).

I suggested "Counting the Cost" Report could help inform?
http://2020health.org/2020health/Publications/Publications-2017/OHC.html

Also the APPG Inquiry (aborted) on Barriers to Access of Social Care.

She was pressing for some "outcome measures".....to guide the debate and NICE- If she meant "Friends and Family Test, (F&FT) ", forget it!
We pressing for some robust Key Performance Indicators for our area but the KPIs suggested we were told were too demanding (ie too revealing).
But even our statistical analysis of the F& FT revealed a worrying decline and reduced satisfaction year on year.
More worrying was the failure to deliver contactual obligations and that was not just waiting times.....with absolutely no consequences for the offending service from the commissioning teams.
Care Quality Commission deliberately ignored complaints too and refused to look at inspection.

So, when this came up today, I thought back to Friday.........
http://healthinsightuk.org/2018/05/28/qof-fiasco-2-immoral-refusal-to-learn-from-mistakes/

QOF Fiasco 2: ’Immoral’ refusal to learn from mistakes
By Jerome Burne
Last week I wrote about the great QOF (Quality and Outcomes Framework) fiasco – the 30-billion-pound public health experiment involving the whole UK population without any kind of testing or pilot programs and without telling patients (in any formal sense) what was going on. Ten years after its launch it was clear that it had almost totally failed. Yet almost no one outside the profession knew about it.

Given its potential impact on our health, this seemed a major scandal that warranted rapid action and proper investigation. This week’s post is about the medical establishment’s remarkable ability to ignore the implications and refusal to do anything about it at all. This failure to even attempt to learn any lessons from it has been described by one professor of public health as a ‘frankly immoral way to conduct policy.’

The policy wasn’t specifically kept secret but the key part of the program – paying GPs for testing for certain health biomarkers and then for prescribing various drugs if they fell above or below them – came as shocking or surprising news to those who did accidently learn about it. That accounted for half the cost, the other half went to pay for the increase in drug prescriptions.
 
Page two of the slide presentations issued to us on Friday;

What does the scope do?
  • Ensures the guideline addresses the key areas of variation in delivery of care and quality

How on earth can this be achieved? There appears no formal mechanism for feedback to NICE about "variation", care or quality!!.
NHS England and NHS Public Health have not addressed this.

Government (D o H and SC) don't collect data on ME CFS Services-
Not all services subscribe to "BACME"-
One of the informed stakeholders involve in NICE before and with BACME (medic) gave out some statistics which are not common knowledge (only 9% of services have a lead ( consultant level?) physician) , most are therapy OT and Physio led; annual average "spend" on a MS patient £80, and ME patient averaged at £4 I think she said (will have to check).

I suggested "Counting the Cost" Report could help inform?
http://2020health.org/2020health/Publications/Publications-2017/OHC.html

Also the APPG Inquiry (aborted) on Barriers to Access of Social Care.

She was pressing for some "outcome measures".....to guide the debate and NICE- If she meant "Friends and Family Test, (F&FT) ", forget it!
We pressing for some robust Key Performance Indicators for our area but the KPIs suggested we were told were too demanding (ie too revealing).
But even our statistical analysis of the F& FT revealed a worrying decline and reduced satisfaction year on year.
More worrying was the failure to deliver contactual obligations and that was not just waiting times.....with absolutely no consequences for the offending service from the commissioning teams.
Care Quality Commission deliberately ignored complaints too and refused to look at inspection.

So, when this came up today, I thought back to Friday.........
http://healthinsightuk.org/2018/05/28/qof-fiasco-2-immoral-refusal-to-learn-from-mistakes/

QOF Fiasco 2: ’Immoral’ refusal to learn from mistakes
By Jerome Burne
Last week I wrote about the great QOF (Quality and Outcomes Framework) fiasco – the 30-billion-pound public health experiment involving the whole UK population without any kind of testing or pilot programs and without telling patients (in any formal sense) what was going on. Ten years after its launch it was clear that it had almost totally failed. Yet almost no one outside the profession knew about it.

Given its potential impact on our health, this seemed a major scandal that warranted rapid action and proper investigation. This week’s post is about the medical establishment’s remarkable ability to ignore the implications and refusal to do anything about it at all. This failure to even attempt to learn any lessons from it has been described by one professor of public health as a ‘frankly immoral way to conduct policy.’

The policy wasn’t specifically kept secret but the key part of the program – paying GPs for testing for certain health biomarkers and then for prescribing various drugs if they fell above or below them – came as shocking or surprising news to those who did accidently learn about it. That accounted for half the cost, the other half went to pay for the increase in drug prescriptions.

We suggested using actometers as an objective measure, but suggested they focus on more of them, over the subjective measures suggested.

BACME have undoubtedly been part of the problem, because until now, their membership criteria 1) require adherence to the so-called 'evidence-based' method (CBT/GET) and 2) require you to agree not to 'harass' researchers and clinicians (which means asking no questions, as we know FOIs and questions are considered vexatious).

BACME has now removed the membership requirements from their website (I think?), which may be in anticipation of the new guidelines. I think they'll struggle, because the old rules weren't about maintaining high quality borne out by evidence but were about maintaining the status quo.

It's very telling that the clinics don't have publicly available audit information or stats. I bet if we saw them, there would be high numbers of discharged patients and/or low success rates.
 
AfME's post on it
Action for M.E. joined stakeholders from patient groups, charities, and professional bodies to take part in Friday's workshop on the scope of the National Institute of Health and Care Excellence (NICE) guideline on M.E/CFS.

The event was part of NICE’s ongoing process to revise its M.E./CFS guideline, with a focus on topics and themes that should be considered for inclusion, rather than the content itself. These included the need for:

  • specific consideration to be given to children, young people and adults who are severely affected
  • objective outcome measures to be prioritised by the committee when reviewing evidence about what to include
  • a section about prevention, risk factors and deterioration to be included in the guideline scope.
“Points raised in my particular discussion group included the clear need for the guideline to reflect our current understanding regarding the aetiology of M.E. – and be clear on what M.E. is not, eg. deconditioning, or Medically Unexplained Symptoms,” says Clare Ogden, Head of Communications and Engagement, Action for M.E., who attended the workshop. “We also asked that the consultation period on the draft scope be extended from four weeks, so that everyone with M.E. has the chance to have a say, including those severely affected.”
https://www.actionforme.org.uk/news/people-with-me-must-be-heard-says-nice-committee/
 
Is there any evidence for making statements about any of these? Do we know how to prevent ME, what the risk factors are, or what causes deterioration?

Its fair to consider them in the guideline scope which I assume says they can look for evidence and give advice on that. I suspect they will find very little evidence but if they do look at what causes deterioration they they may find some evidence for too much activity (or anecdotal evidence from patients).

I think the scope suggests what they will look at not what the results will be.

It would of course be very bad if they looked at and believed Chadler's badly done mediation analysis which is badly applying statistical methods to uninterpretable data.
 
Firstly, any physician can use options like this if they want anyway.
My experience of GPs is that they seem to have tighter constraints on what they can prescribe than we expect. Even if this is not true, in my support group I know of some whose GP refuses to prescribe medication to help with pain because ME is "purely psychological".

Many folk with ME have no specialist centre, or have one that is purely "Yes, you've got ME, here's the therapy team." They become totally dependent on the attitude of their GP. The NICE guidelines cannot really change this, but the tone of their guidelines could influence the approach of some GPs. Well, that's my optimism talking.
 
Objective outcome measures and "fatigue scales"- In our group I suggested that BACME acolytes and our local service, used the "Chandler Fatigue Scale"- which is long, demanding and patient unfriendly, local patients think it is a waste of time and energy_ plus it is "licensed" and has to be paid for- or so the Norfolk & Suffolk (East Coast Community Health) clinic told us!!? NICE seemed surprised it has to be paid for!

Now ECCH might be telling porkies.... Does any one know it it has to be paid for and, if so, how much?

Is Recovery from Chronic Fatigue Syndrome Possible?
Published: March 27th, 2013
Category: Blog-Posts

"Chronic Fatigue Syndrome (ME/CFS) is a multifaceted and complex condition characterized by debilitating fatigue, impairments in concentration, and musculoskeletal pain.
About 5 years ago, the UK government issued funding for a large scale study investigating the efficacy and safety of various treatments for ME/CFS, known as the PACE trial
the release of these findings, several key criticisms came to light.........
First, the results of the PACE study used the Oxford selection criteria as opposed to the CDC criteria, meaning that some of the participants might not qualify as having ME/CFS according to internationally accepted CDC criteria. Second, the protocol was changed during the trial. Third, the Chandler Fatigue Scale, designed by one of the researchers, was used by participants to rate fatigue, but it has not yet been accepted as an objective and scientific method for measuring fatigue. All of these factors could confound the results."

Meriem Mokhtech, BS
UF Center for Musculoskeletal Pain Research
https://rheum.med.ufl.edu/2013/03/27/is-recovery-from-chronic-fatigue-syndrome-possible/
 
Its fair to consider them in the guideline scope which I assume says they can look for evidence and give advice on that. I suspect they will find very little evidence but if they do look at what causes deterioration they they may find some evidence for too much activity (or anecdotal evidence from patients).

I think the scope suggests what they will look at not what the results will be.

It would of course be very bad if they looked at and believed Chadler's badly done mediation analysis which is badly applying statistical methods to uninterpretable data.
@dave30th perhaps worth highlighting this given the need for evidence based info has included LP .
 
I'm pleased with Clare's statement and AfME's points here. I think it means the message has got through, clearly.

I'm glad AfME raised aetiology too. I'm not sure if it should be included in the scope or not, but last time exercise studies were excluded because they were considered to be about aetiology (i.e., they were proposing a model of ME and why exercise would be dangerous based on that model). That meant GET studies got through but the papers contradicting them didn't.
 
Until now the horse has been too easily distracted by the loud quacking of the ducks who seem to have taken over the village pond. Ideally the ducks should be removed as in such numbers they are a pest and a nuisance. Failing that, we have to educate the horse to accept the fact that although ducks will quack because that's what ducks do, they should not be allowed to prevent it from having a good drink, which is what it came to the pond for in the first place.

Bloody ducks.

There is a rider on top of a very badly trained and viscous horse. It's kicked and bitten before.

It remains to be seen how long the rider is in control and if the water is really there or just a small puddle.

Very few of the issues identified in the original meeting with NICE 17/1 went into the Draft Scope. It's over to written submissions to the Scope to be released 20/6 and then few of us will have anything to do with them again apart from what we can influence from writing.

The patients on the new GDG may be as toothless as the last lot and manipulated and managed.

Our two meetings are over. Now it's down to what else we can do which is practical and can influence the outcome like writing our submissions to the next part of the consultation and trying to find good people (of all the desired disciplines) to serve on the GDG.
 
I'm pleased with Clare's statement and AfME's points here. I think it means the message has got through, clearly.

I'm glad AfME raised aetiology too. I'm not sure if it should be included in the scope or not, but last time exercise studies were excluded because they were considered to be about aetiology (i.e., they were proposing a model of ME and why exercise would be dangerous based on that model). That meant GET studies got through but the papers contradicting them didn't.

But did AFME raise Aetiology at the meeting?

Did anyone hear them raise any of these points
 
Last edited:
There is a rider on top of a very badly trained and viscous horse. It's kicked and bitten before.

My sentiment completely and, if we ask who this Guideline is aimed at.....essentially Primary care , 'cos that is effectively all there is atm.
AND in our local regional experience, after a 13 year intensive spat, you can lead a CCG horse to water but will the buggers drink....?
Absolutely NOT! Not only that, they have slipped the reins, massed within Community Interest Groups CIC and therefore cannot be challenged by the public- refuse FOI, 'cos they are effectively "private companies" answering only to Companies' House and an Annual Report....

Cynical I am and today This is what I was sent. https://suffolkfed.org.uk/chair-blog/you-ask-what-is-our-aim/

You ask – what is our aim?

Posted: 20th April 2018

Those familiar with the recent Churchill films will be well aware of his bombastic speeches. His answer, of course, was: “Victory… at all costs”.

The Fed’s aims are more modest: “to support primary care…at reasonable cost”.
 
My table was made up of people who are pretty much all singing from the same hymn sheet. I felt the discussion got slightly diverted to discussing names (I.e. people saying we need to separate ME and CFS) which I found a bit frustrating. I was mainly bringing up points about evidence, needing objective outcomes, that they need to consider critical literature etc. and again the NICE official on my table seemed aware and onboard and told me that they would be more critical when they look at ‘evidence’ this time.

I don't understand how a discussion on ME vs CFS could be considered diverting given that we were there to discuss the Scope and the Scope started with a statement on umbrella term etc. It may be that they were discussing this in a general way and not tied into the Scope though...

I've seen the submission from the 25% group to NICE and they are very concerned about the use of ME and CFS. They representing the severely affected and it may be that some groups have different ideas on what in the Scope was important and not important.
 
Last edited:
While there are no firm evidences for a mechanism, there have been many studies that tend to show that there is something abnormal happening (I'm thinking about metabolomics or exercise studies...). We don't know yet the importance of these abnormalities, the role they play, if they discriminate from other pathological states etc, but they are nonetheless there.

I do not think they should be presentend as "firm evidences", but I do not think they should be discarded either, on the ground that the pathophysiology is not yet understood.

We don't to prove firm evidence but only that there are abnormalities and what they are. We can explain how mixing groups for research is maybe producing different answers as well.

Just an explanation of what we know at the moment.
 
Is there any evidence for making statements about any of these? Do we know how to prevent ME, what the risk factors are, or what causes deterioration?

Patient surveys on exercise and harms
Reports on outbreaks i.e. Giardia in Norway
The Dubbo report showing severity of initial illness

This feeds into Aetiology and what evidence on exercise as an example

(BTW AFME didn't bring these topics up at the meeting unless it was at another table?)
 
I don't understand how a discussion on ME vs CFS could be considered diverting given that we were there to discuss the Scope and the Scope started with a statement on umbrella term etc. It may be that they were discussing this in a general way and not tied into the Scope though...

I've seen the submission from the 25% group to NICE and they are very concerned about the use of ME and CFS. They representing the severely affected and it may be that some groups have different ideas on what in the Scope was important and not important.

Yes of course we discussed the umbrella statement the importance of names etc. I know names and labels are important.
I just worry that spending a lot of time talking about how CFS isn't ME and vice versa isn't always helpful when there's so much to discuss. I mean specifically the idea that CFS and ME are two discrete illnesses.

I'd love to read their submission if it is publically available - do you know if I can?
 
Last edited:
I just worry that spending a lot of time talking about how CFS isn't ME and vice versa isn't always helpful when there's so much to discuss. I mean specifically the idea that CFS and ME are two discrete illnesses.

There isn't really any evidence to point to in these areas. Without a good understanding of mechanisms its just clustering of reported symptoms and people making guesses over what is important/different.
 
Back
Top Bottom